An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART

Trial Profile

An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Romidepsin (Primary) ; Vacc-4x (Primary) ; Sargramostim
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REDUC
  • Sponsors Bionor Pharma
  • Most Recent Events

    • 26 Jul 2017 Results of a study assessing the phylogenetic relationship between circulating proviruses, stimulated outgrowth viruses and rebound viremia presented at the 9th International AIDS Society Conference on HIV Science
    • 26 Jul 2017 Results assessing functional T-cell responses following Vacc-4x/GM-CSF immunotherapy in relation to virological outcomes on HIV reservoir measurements presented at the 9th International AIDS Society Conference on HIV Science
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top